These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30892008)

  • 21. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 23. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
    Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
    Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].
    Fang F; Qiao XB; Yang L; Di J; Hu ST; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):270-275. PubMed ID: 30955261
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells.
    Dong J; Jan YJ; Cheng J; Zhang RY; Meng M; Smalley M; Chen PJ; Tang X; Tseng P; Bao L; Huang TY; Zhou D; Liu Y; Chai X; Zhang H; Zhou A; Agopian VG; Posadas EM; Shyue JJ; Jonas SJ; Weiss PS; Li M; Zheng G; Yu HH; Zhao M; Tseng HR; Zhu Y
    Sci Adv; 2019 Jul; 5(7):eaav9186. PubMed ID: 31392269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments.
    Stridfeldt F; Cavallaro S; Hååg P; Lewensohn R; Linnros J; Viktorsson K; Dev A
    Talanta; 2023 Jul; 259():124553. PubMed ID: 37084607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.
    Sun N; Lee YT; Zhang RY; Kao R; Teng PC; Yang Y; Yang P; Wang JJ; Smalley M; Chen PJ; Kim M; Chou SJ; Bao L; Wang J; Zhang X; Qi D; Palomique J; Nissen N; Han SB; Sadeghi S; Finn RS; Saab S; Busuttil RW; Markovic D; Elashoff D; Yu HH; Li H; Heaney AP; Posadas E; You S; Yang JD; Pei R; Agopian VG; Tseng HR; Zhu Y
    Nat Commun; 2020 Sep; 11(1):4489. PubMed ID: 32895384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1].
    Wu D; Li J; Yao MH; Zheng YH; Feng CY; Yang YH
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):251-253. PubMed ID: 33677892
    [No Abstract]   [Full Text] [Related]  

  • 33. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
    Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W; Song Z; Zhang Y
    Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
    Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
    Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular Vesicles from
    Janpipatkul K; Panvongsa W; Worakitchanon W; Reungwetwattana T; Chairoungdua A
    Anticancer Res; 2022 Aug; 42(8):3835-3844. PubMed ID: 35896267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.
    Toffart AC; Dhalluin X; Girard N; Chouaid C; Audigier-Valette C; Duruisseaux M; Mennecier B; Parrot A; Fournel P; Moro-Sibilot D; Timsit JF
    Intensive Care Med; 2015 Jan; 41(1):164-5. PubMed ID: 25366122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.